NCT07032818 Adapted Hospital Discharge Intervention: the CONNECT Pilot
| NCT ID | NCT07032818 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Medical Center |
| Condition | Communication Research |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-01-16 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-01-16 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hospital discharge is a dangerous time for patients: one in five will suffer an adverse event, such as a medication error, and nearly 25% will be readmitted within 30 days. This time is even more dangerous for patients with who face communication barriers, including those with non-English language preference (NELP), low health literacy, and the elderly. The investigators will pilot a post-discharge educational intervention to reinforce written discharge instructions (known as the After Visit Summary or AVS) using a randomized controlled trial design (2:1 intervention: control). The control group will receive current standard of care discharge education which includes a nurse reviewing their AVS and an automated call in English that allows patients to numerically select types of problems/questions that are then escalated to a nurse who should return their call within a few days. The intervention group will receive the standard of care discharge education with the AVS and an additional post-discharge educational call delivered by a registered nurse or other qualified health professional with the option to have written instructions professionally translated and sent via MyChart message--if available in their preferred language.
Eligibility Criteria
Inclusion Criteria: * Registered language in Epic (written or spoken) is Spanish, Haitian Creole, Portuguese, Cape Verdean, or Vietnamese * Admitted to medicine team at Boston Medical Center (BMC) * Being discharged home (to the community) Exclusion Criteria: * On airborne infections precautions at time of recruitment * On C diff precautions at time of recruitment * On suicide precautions at time of recruitment * Nurse report of participant displaying cognitive impairment, ongoing delirium, or aggression * Discharge observed during a prior admission
Contact & Investigator
Kirsten Austad, MD MPH
PRINCIPAL INVESTIGATOR
Boston Medical Center, Family Medicine
Frequently Asked Questions
Who can join the NCT07032818 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Communication Research. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07032818 currently recruiting?
Yes, NCT07032818 is actively recruiting participants. Contact the research team at kirsten.austad@bmc.org for enrollment information.
Where is the NCT07032818 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT07032818 clinical trial?
NCT07032818 is sponsored by Boston Medical Center. The principal investigator is Kirsten Austad, MD MPH at Boston Medical Center, Family Medicine. The trial plans to enroll 60 participants.